You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Triple Negative Breast Neoplasms

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Triple Negative Breast Tumors Trial (Xiaopi granules, Xiaopi decoction, Placebo)

Not yet recruiting
  • Triple Negative Breast Neoplasms
  • Xiaopi granules
  • +2 more
  • (no location specified)
Nov 22, 2023

Triple Negative Breast Tumors Trial (Pembrolizumab injection, Capecitabine tablets, Local radiotherapy)

Not yet recruiting
  • Triple Negative Breast Neoplasms
  • Pembrolizumab injection
  • +2 more
  • (no location specified)
Jul 25, 2023

Triple Negative Breast Tumors Trial in Paris (Atezolizumab + RP1)

Not yet recruiting
  • Triple Negative Breast Neoplasms
  • Atezolizumab + RP1
  • Paris, France
    Institut Curie
Oct 2, 2023

Triple Negative Breast Cancer Trial (Proleukin 1.3 MG Injection)

Not yet recruiting
  • Triple Negative Breast Cancer
  • Proleukin 1.3 MG Injection
  • (no location specified)
Apr 6, 2023

Immunotherapy-related CRP Kinetics in Early and Metastatic

Recruiting
  • TNBC - Triple-Negative Breast Cancer
    • Tuebingen, Germany
      Department of Women's Health
    Jun 13, 2023

    Looking At Triple Negative Breast Cancer Patient Experience

    Not yet recruiting
    • Triple Negative Breast Cancer
    • Breast Cancer
      • (no location specified)
      Mar 3, 2023

      Breast Cancer Trial in Beijing (99mTc-MY6349 SPECT/CT scan)

      Recruiting
      • Breast Cancer
      • 99mTc-MY6349 SPECT/CT scan
      • Beijing, Beijing, China
        Peking Union Medical College Hospital
      Oct 24, 2023

      Triple Negative Breast Cancer, Neoadjuvant Chemo, Pembrolizumab Trial in Seoul (Visium, Whole Genome Sequencing(WGS)/Whole

      Recruiting
      • Triple Negative Breast Cancer
      • +3 more
      • Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)
      • Seoul, Korea, Republic of
        Samsung Medical Center
      Jun 15, 2023

      Triple Negative Breast Cancer Trial in Dhaka (Doxorubicin, Cyclophosphamide, Paclitaxel)

      Not yet recruiting
      • Triple Negative Breast Cancer
      • Dhaka, Bangladesh
        Bangabandhu Sheikh Mujib Medical University
      May 24, 2023

      TNBC - Triple-Negative Breast Cancer Trial (Alkaline Glucosodiene Molecules)

      Not yet recruiting
      • TNBC - Triple-Negative Breast Cancer
      • Alkaline Glucosodiene Molecules
      • (no location specified)
      Jul 14, 2023

      Breast Cancer, Triple Negative Breast Cancer Trial (Antivascular therapy, Chemotherapy)

      Not yet recruiting
      • Breast Cancer
      • Triple Negative Breast Cancer
      • (no location specified)
      Jun 11, 2023

      TNBC - Triple-Negative Breast Cancer Trial in Wuhan (Utidelone, Tirelizumab, Bevacizumab)

      Recruiting
      • TNBC - Triple-Negative Breast Cancer
      • Wuhan, Hubei, China
        Tongji Hospital Affiliated of Tongji Medical College Huazhong Un
      Nov 5, 2023

      Triple Negative Breast Cancer Trial (Sacituzumab govitecan, Pembrolizumab)

      Not yet recruiting
      • Triple Negative Breast Cancer
      • (no location specified)
      Oct 5, 2023

      Metastatic Triple-Negative Breast Cancer Trial in Charlotte (Trilaciclib, Pembrolizumab, Gemcitabine)

      Not yet recruiting
      • Metastatic Triple-Negative Breast Cancer
      • Charlotte, North Carolina
        Levine Cancer Institute
      Aug 31, 2023

      TNBC - Triple-Negative Breast Cancer Trial in Brussels (Ga-PSMA PET/CT)

      Recruiting
      • TNBC - Triple-Negative Breast Cancer
      • Ga-PSMA PET/CT
      • Brussels, Belgium
        Institut Jules Bordet
      Sep 26, 2023

      Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant

      Not yet recruiting
      • Breast Cancer Triple Negative
      • +3 more
        • Atlanta, Georgia
          Emory University/Winship Cancer Institute
        May 18, 2023

        Breast Tumors Trial in Hangzhou (Sindilimab, Nab-paclitaxel, Lenvatinib)

        Not yet recruiting
        • Breast Neoplasms
        • Hangzhou, Zhejiang, China
          ZhejiangCH
        Nov 17, 2023

        Triple Negative Breast Cancer, Residual Disease Trial (Tetrathiomolybdate, Capecitabine, Pembrolizumab)

        Not yet recruiting
        • Triple Negative Breast Cancer
        • Residual Disease
        • (no location specified)
        Nov 15, 2023

        Breast Cancer, Inflammatory Breast Cancer Stage IV, Inflammatory Breast Tumors Trial in Knoxville (Self-Administered Hypnosis,

        Recruiting
        • Breast Cancer
        • +4 more
        • Self-Administered Hypnosis
        • Self-Administered White Noise Hypnosis
        • Knoxville, Tennessee
          University of Tennessee Knoxville
        Sep 26, 2023

        Triple Negative Breast Cancer, HER2-positive Breast Cancer Trial in Shanghai (proton plus carbon ion radiotherapy)

        Recruiting
        • Triple Negative Breast Cancer
        • HER2-positive Breast Cancer
        • proton plus carbon ion radiotherapy
        • Shanghai, China
          Shanghai Proton and Heavy Ion center
        Jan 11, 2023

        Breast Cancer Stage IV Trial in Vienna (Datopotamab deruxtecan)

        Recruiting
        • Breast Cancer Stage IV
        • Datopotamab deruxtecan
        • Vienna, Austria
          AKH Universitaetsklinikum Vienna, Department f. Internal medicin
        May 19, 2023

        Breast Cancer, Triple Negative Breast Cancer Trial in Gothenburg (Imatinib 400 MG Oral Tablet)

        Not yet recruiting
        • Breast Cancer
        • Triple Negative Breast Cancer
        • Imatinib 400 MG Oral Tablet
        • Gothenburg, Sweden
          Barbro Linderholm
        Feb 1, 2023

        Triple Negative Breast Cancer Trial (Cryoablation, Cryoablation combined with PD1 Inhibitor)

        Not yet recruiting
        • Triple Negative Breast Cancer
        • Cryoablation
        • Cryoablation combined with PD1 Inhibitor
        • (no location specified)
        Mar 28, 2023

        Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in

        Not yet recruiting
        • Metastatic Triple-Negative Breast Carcinoma
        • 89Zr-atezolizumab PET/CT
        • (no location specified)
        Feb 22, 2023

        TNBC - Triple-Negative Breast Cancer Trial (Camrelizumab Plus Chemotherapy and Famitinib, Camrelizumab Plus Chemotherapy)

        Not yet recruiting
        • TNBC - Triple-Negative Breast Cancer
        • Camrelizumab Plus Chemotherapy and Famitinib
        • Camrelizumab Plus Chemotherapy
        • (no location specified)
        Aug 17, 2023